The absence of appropriate warning labels on critical care drugs introduced in the US to alleviate shortages created by the COVID-19 pandemic, have prompted the Institute for Safe Medication Practices (ISMP) to issue an alert to the United States healthcare community.

The organisation is concerned that the absence of the standard vial cap label \"Warning: Paralysing Agent\" on neuromuscular-blocking agents, may make them look similar to other medications in similar-sized vials and cap colours increasing the potential for mix-ups if they are stored together. When used incorrectly, these drugs can have catastrophic outcomes, and the ISMP is urging organisations to alert their staff, review their storage areas and affix their own warning labels upon receipt of the products.

An overseas propofol product known as Propoven 2% will be made available in the US under an emergency use authorisation that restricts its use to sedation maintenance in patients requiring ventilation during the COVID-19 pandemic. This product contains twice the propofol concentration of the FDA-approved Diprivan and the ISMP is concerned that without a warning label to highlight this, there is risk of overdose if practitioners are unaware.

It recommends that an interdisciplinary committee comprising those professions associated with critical care, review the Propoven 2% product prior to use and that warning labels be applied to the Propoven 2% vials as soon as the product is received by the pharmacy.
